Research has found that a first-generation antagonist of S1PRs (S1PR1, S1PR3, S1PR4, and S1PR5), fingolimod (FTY720), inhibits tumor growth and metastasis and increases the chemosensitivity of advanced and hormonal refractory BRCA and TNBC by downregulating S1PR1 [34–36]. This evidence concerns the gene S1PR1 and neoplasm.